Northern Trust Corp Kinnate Biopharma Inc. Transaction History

Northern Trust Corp

$572 Billion
Q1 2024

A detailed history of Northern Trust Corp transactions in Kinnate Biopharma Inc. stock. As of the latest transaction made, Northern Trust Corp holds 27,778 shares of KNTE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,778

Previous 27,778 -0.0%

Holding current value

Previous $65,000 12.31%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.38 - $3.31 $318 - $764	-231 Reduced 0.82%	27,778 $38,000
Q2 2023 Aug 11, 2023	SELL	$2.33 - $6.84 $428,361 - $1.26 Million	-183,846 Reduced 86.78%	28,009 $84,000
Q1 2023 May 15, 2023	SELL	$3.46 - $7.98 $10,245 - $23,628	-2,961 Reduced 1.38%	211,855 $1.32 Million
Q4 2022 Feb 13, 2023	SELL	$5.26 - $12.19 $30,550 - $70,799	-5,808 Reduced 2.63%	214,816 $1.31 Million
Q3 2022 Nov 14, 2022	SELL	$9.86 - $15.76 $49,122 - $78,516	-4,982 Reduced 2.21%	220,624 $2.64 Million

Q2 2022 Aug 12, 2022	BUY	$7.43 - $13.0 $132,023 - $230,997	17,769 Added 8.55%	225,606 $2.85 Million
Q1 2022 May 13, 2022	SELL	$7.73 - $17.99 $44,061 - $102,542	-5,700 Reduced 2.67%	207,837 $2.34 Million
Q4 2021 Feb 08, 2022	BUY	$16.5 - $25.48 $36,036 - $55,648	2,184 Added 1.03%	213,537 $3.78 Million
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $1.35 Million - $1.89 Million	75,840 Added 55.97%	211,353 $4.87 Million
Q2 2021 Aug 13, 2021	SELL	$22.19 - $31.55 $224,008 - $318,497	-10,095 Reduced 6.93%	135,513 $3.16 Million
Q1 2021 May 12, 2021	BUY	$26.99 - $40.0 $3.93 Million - $5.82 Million	145,608 New	145,608 $4.54 Million

Others Institutions Holding KNTE

# of Institutions

Shares Held

32.9M

Call Options Held

94.7K

Put Options Held

802K

View Full List

About Kinnate Biopharma Inc.

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

More about KNTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Kinnate Biopharma Inc. Transaction History